Journal
Journal: Compounding Regulation, Cost and Evidence Analysis
Long-form analysis of compounding regulation, cost, enforcement and evidence — each piece built from the datasets that drive the rest of this platform.
Direct answer
30 pieces covering regulation, cost, verification, enforcement, safety, evidence and standards. Every figure traces to a dated capture or an FDA primary source, and the underlying tables and charts are published on each page so the reasoning is checkable.
Key findings
- 30 long-form pieces across seven categories.
- Every figure drawn from a dated capture or FDA primary source.
- Pricing analysis covers 92 offerings across 22 providers.
- Regulatory analysis is anchored to the verified FDA compounding timeline.
- No provider pays for coverage or placement.
| Pieces | 30 |
|---|---|
| Categories | 7 |
| Pricing dataset | 70 offerings |
| Framework sources | FDA, verified 2026-07-23 |
| Provider relationship | No Public Evidence Found no financial relationship exists |
Evidence status Response Received dated captures and FDA primary sources
Verified 2026-07-23
Reviewer CompoundedRxMonitor Regulatory Desk
Snapshot 2026-07-23
Methodology v1.0
All pieces
Is Compounded GLP-1 Still Legal in 2026?Both shortages resolved and enforcement discretion expired in 2025. What remains lawful is narrower than most 503A vs 503B: The Difference That Decides EverythingOne dispenses against patient prescriptions under state licence; the other registers federally and answers to The Cheapest GLP-1 in 2026 Is Not What You ThinkAn FDA-approved oral pill at $149 now undercuts most of the compounded market.Compounded vs Brand: The Price Gap Has CollapsedThe discount that built this market is far smaller than it was in 2023.How to Verify a Compounding Pharmacy in Ten MinutesThree public registers answer most of what matters, and a refusal to name the pharmacy is itself the finding.What a Form 483 Actually MeansObservations at the close of an inspection, not a final finding — and 53 of 55 inspected 503Bs have one.Warning Letter vs Form 483: Why the Difference MattersOne is an investigator's observation; the other is the agency's stated position on violations.FDA Registration Is Not FDA ApprovalRegistration means the agency received a filing. It says nothing about approval or CGMP compliance.Semaglutide Sodium and Acetate Are Not SemaglutideA different active moiety, and FDA has stated the salt forms are not appropriate for compounding.Microdosing GLP-1s: What the Evidence Actually ShowsNo randomised trial has evaluated any dose below the studied range.Sublingual and ODT GLP-1s: The Bioavailability QuestionNo approved sublingual product exists, and injectable trial data does not transfer across routes.The Multi-Dose Vial ProblemDosing mistakes by a factor of ten, and an approved pen removes the failure mode entirely.Who Actually Makes Your GLP-1Six parties get collapsed into one phrase, and only one of them holds the record that matters.Membership Fees: The Hidden Half of the PriceA $99 headline plus a required $99 membership is a $198 programme.What Happens to Your Price at Maintenance DoseFlat pricing and escalating pricing diverge sharply once titration finishes.Nonresident Licences: The Board You Did Not ExpectTwo boards are involved in most mail-order prescriptions and they hold different records.USP Chapter 797 and What Sterile Actually RequiresCleanroom classification, environmental monitoring, and beyond-use dates measured in days.Beyond-Use Dates Are Not Expiry DatesOne comes from category rules, the other from formal stability testing.The 503B Bulks List Proposal ExplainedFDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026.How the Shortage List Created and Ended a MarketA binary switch: on the list, copies are lawful; off it, they are not.What the Adverse Event Data Shows455+ reports for semaglutide, 320+ for tirzepatide, with dosing errors recurring.The 503B Inspection Gap39 of 48 newly registered facilities had never been inspected as of July 2025.Your Telehealth Provider Is Not a PharmacyProviders hold no compounding licence and appear on no federal facility register.Liraglutide: Cheaper Is Not the WordDaily injection, roughly 8% mean reduction against 14.9% and 20.9% — and it is not cheaper.A Capped Dose Is Not a DiscountA programme capped at 0.6 mg is a lower-dose treatment, not a cheaper version of the same one.Introductory Pricing and What It BecomesEleven of 92 offerings quote a first-month rate; the ongoing number is what matters.Prepaying Twelve Months: The Risk Nobody PricesThe discount is real; so is the exposure if treatment stops in month two.Reading a Drug Recall CorrectlyScope is limited to the products and lots named, and current is not the same as historical.Where 503B Capacity Actually SitsFlorida and Texas hold 16 each of 96 registrations; the South holds 47.Everything That Changed in 2026The bulks-list proposal, the approved oral pill, and a market repricing around both.
What this means
- Each piece is anchored to a dataset published on this platform.
- Pricing, enforcement and regulatory claims carry their own capture dates.
- Charts and tables are shown so the reasoning can be checked rather than trusted.
What this does not mean
- That any named entity is endorsed or assessed here.
- That a cheaper option is a better-evidenced one.
- That any provider paid for inclusion.
Independence statement. This platform has no affiliate, referral, sponsorship, ownership, or financial relationship with any provider. Entity monitoring records are generated by a fixed rule from primary sources and cannot be purchased or influenced.
Limitations of this record.
- Pricing captures are dated and change; confirm at checkout.
- Regulatory positions change through rulemaking and enforcement.
- Nothing here is legal or medical advice.
Frequently asked questions
What is the journal for?
Analysis that draws on the platform's datasets rather than repeating regulatory summaries.
Are these sponsored?
No. This platform has no affiliate, referral, sponsorship, or financial relationship with any provider.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.